Study on the clinical efficacy and mechanism of compound Guizhencao granule in the treatment of grade I patients with hypertension based on metabolomics Technology
- Conditions
- hypertension
- Registration Number
- ITMCTR2200006054
- Lead Sponsor
- The First Affiliated Hospital of Henan University of traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- Not specified
(1) Meet the grade I diagnostic criteria of hypertension, and the risk stratification is low-risk or medium-risk;
(2) Not taking antihypertensive drugs in the past or taking antihypertensive drugs regularly;
(3) Between 35-55 years old;
(4) Agree to sign informed consent.
(1) Patients with hypertension grade II or above;
(2) Hypertensive patients with severe target organ damage of liver, kidney, heart and brain;
(3) Allergic constitution, or allergic to a variety of drugs and food;
(4) Women who have pregnancy plans or are pregnant or lactating;
(5) Patients who cannot take care of themselves or oral drugs;
(6) Participate in other clinical researchers within one month;
(7) Suspected or true history of alcohol and drug abuse; Or the study believes that there are patients with inappropriate inclusion factors.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TCM syndrome score;24-hour ambulatory blood pressure;Metabonomics test;
- Secondary Outcome Measures
Name Time Method electrolyte;interleukin 6,IL-6;urinalysis;Endothelin-1;Routine blood test;Interleukin-1ß;Renal function;catecholamine;Tumor necrosis factor-a;liver function;